Evidence map›Paper›PMID 29502324›Full record

ArticleBreast cancer research and treatment2018

Does mammographic density mediate risk factor associations with breast cancer? An analysis by tumor characteristics.

Megan S Rice, Rulla M Tamimi, Kimberly A Bertrand, Christopher G Scott, Matthew R Jensen, Aaron D Norman, Daniel W Visscher, Yunn-Yi Chen, Kathleen R Brandt, Fergus J Couch and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. A Metabolomics Analysis of Circulating Carotenoids and Breast Cancer Risk.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 1 country.

Megan S RiceClinical and Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital/Harvard Medical School, 55 Fruit Street, Bartlett 9, Boston, MA, 02116, USA. mrice1@mgh.harvard.edu.
Rulla M TamimiChanning Division of Network Medicine, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA.
Kimberly A BertrandSlone Epidemiology Center, Boston University, Boston, MA, USA.
Christopher G ScottDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Matthew R JensenDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Aaron D NormanDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Daniel W VisscherDepartment of Anatomic Pathology, Mayo Clinic, Rochester, MN, USA.
Yunn-Yi ChenDepartment of Pathology, University of California, San Francisco, CA, USA.
Kathleen R BrandtDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Fergus J CouchDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
John A ShepherdDepartment of Radiology, University of California, San Francisco, CA, USA.
Bo FanDepartment of Radiology, University of California, San Francisco, CA, USA.
Fang-Fang WuDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Lin MaDepartment of Medicine, University of California, San Francisco, CA, USA.
Laura C CollinsDepartment of Pathology, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, USA.
Steven R CummingsSan Francisco Coordinating Center, California Pacific Medical Center Research Institute, San Francisco, CA, USA.
Karla KerlikowskeDepartments of Epidemiology and Biostatistics and General Internal Medicine Section, Department of Veterans Affairs, University of California, San Francisco, CA, USA.
Celine M VachonDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Mayo Clinic in Florida · USUniversity of California, San Francisco · USHarvard University · USMayo Clinic in Arizona · USBoston University · USBrigham and Women's Hospital · USCalifornia Pacific Medical Center · US

Funding

Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI TWOROGER, SHELLEY S · 2000 to 2019
$77.8M
Risk-based Imaging Strategies to Improve Breast Cancer Surveillance OutcomesP01CA154292 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Diana L Miglioretti · 2011 to 2026
$52.9M
The Role of CHFR in Tumorigenesis and Paclitaxel-Sensitivity in Breast CancerP50CA116201 · NCI · MAYO CLINIC ROCHESTER · PI PETER C LUCAS · 2005 to 2026
$49.9M
Tissue and Outcomes CoreP50CA058207 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRAY, JOE W. · 1992 to 2012
$32.7M
Risk Factors for Breast Cancer in Younger NursesR01CA050385 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI ELIASSEN, A. HEATHER, WILLETT, WALTER C. · 1989 to 2019
$32.3M
Life Course Cancer Epidemiology Cohort in WomenU01CA176726 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI ELIASSEN, A. HEATHER, WILLETT, WALTER C. · 2018 to 2025
$22.4M
Long Term Multidisciplinary Study of Cancer in Women: The Nurses Health StudyUM1CA186107 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, STAMPFER, MEIR · 2014 to 2023
$22.3M
Life Course Cancer Epidemiology Cohort in WomenUM1CA176726 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI WILLETT, WALTER C. · 2013 to 2017
$15.7M
San Francisco Mammography Registry-A Research SourceU01CA063740 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KERLIKOWSKE, KARLA M · 1994 to 2011
$6.2M
A Mayo Cohort Study of Mammographic Breast DensityR01CA097396 · NCI · MAYO CLINIC ROCHESTER · PI VACHON, CELINE M · 2003 to 2007
$3.1M
Identifying Genes for Mammographic Breast DensityR01CA128931 · NCI · MAYO CLINIC ROCHESTER · PI VACHON, CELINE M · 2008 to 2012
$2.7M
Risk factors for breast cancer molecular subtypesR01CA140286 · NCI · MAYO CLINIC ROCHESTER · PI KERLIKOWSKE, KARLA M, VACHON, CELINE M · 2010 to 2014
$2.6M
National Institutes of Health P01CA087969National Institutes of Health P01 CA154292National Institutes of Health P50 CA116201National Institutes of Health P50 CA58207National Institutes of Health R01 CA050385National Institutes of Health R01 CA124865National Institutes of Health R01 CA128931National Institutes of Health R01 CA131332National Institutes of Health R01 CA140286National Institutes of Health R01 CA97396National Institutes of Health U01 CA63740National Institutes of Health UM1 CA176726National Institutes of Health UM1 CA186107NCI NIH HHS P01 CA087969NCI NIH HHS P01 CA154292NCI NIH HHS P50 CA058207NCI NIH HHS P50 CA116201NCI NIH HHS R01 CA050385NCI NIH HHS R01 CA097396NCI NIH HHS R01 CA124865NCI NIH HHS R01 CA128931NCI NIH HHS R01 CA131332NCI NIH HHS R01 CA140286NCI NIH HHS U01 CA063740NCI NIH HHS U01 CA176726NCI NIH HHS UM1 CA176726NCI NIH HHS UM1 CA186107U.S. Department of Defense DAMD 17-00-1-033
6 · The paper itself

Abstract

backgroundThough mammographic density (MD) has been proposed as an intermediate marker of breast cancer risk, few studies have examined whether the associations between breast cancer risk factors and risk are mediated by MD, particularly by tumor characteristics.

methodsOur study population included 3392 cases (1105 premenopausal) and 8882 (3192 premenopausal) controls from four case-control studies. For established risk factors, we estimated the percent of the total risk factor association with breast cancer that was mediated by percent MD (secondarily, by dense area and non-dense area) for invasive breast cancer as well as for subtypes defined by the estrogen receptor (ER+/ER-), progesterone receptor (PR+/PR-), and HER2 (HER2+/HER2-). Analyses were conducted separately in pre- and postmenopausal women.

resultsPositive associations between prior breast biopsy and risk of invasive breast cancer as well as all subtypes were partially mediated by percent MD in pre- and postmenopausal women (percent mediated = 11-27%, p ≤ 0.02). In postmenopausal women, nulliparity and hormone therapy use were positively associated with invasive, ER+ , PR+ , and HER2- breast cancer; percent MD partially mediated these associations (percent mediated ≥ 31%, p ≤ 0.02). Further, among postmenopausal women, percent MD partially mediated the positive association between later age at first birth and invasive as well as ER+ breast cancer (percent mediated = 16%, p ≤ 0.05).

conclusionPercent MD partially mediated the associations between breast biopsy, nulliparity, age at first birth, and hormone therapy with risk of breast cancer, particularly among postmenopausal women, suggesting that these risk factors at least partially influence breast cancer risk through changes in breast tissue composition.

Indexed as

Breast DensityAdultAgedBiomarkers, TumorBreastBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleHumansMammographyMiddle AgedPregnancyReceptors, EstrogenReceptors, ProgesteroneRisk FactorsBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneBreast cancerMammographic density

Identifiers

PMID29502324
PMCPMC5994184
OpenAlexW2789255434

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.